186 related articles for article (PubMed ID: 26044064)
1. Systemic adalimumab induces peripheral corneal infiltrates: a case report.
Matet A; Daruich A; Beydoun T; Cosnes J; Bourges JL
BMC Ophthalmol; 2015 Jun; 15():57. PubMed ID: 26044064
[TBL] [Abstract][Full Text] [Related]
2. Internuclear ophthalmoplegia associated with anti-TNFα medication.
Drury J; Hickman SJ
Strabismus; 2015; 23(1):30-2. PubMed ID: 25790247
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab-induced psoriatic alopecia/alopecia areata-like reaction in a patient with Crohn's disease.
Toda-Brito H; Lopes L; Soares-Almeida L; Filipe P
Dermatol Online J; 2015 Nov; 21(11):. PubMed ID: 26632930
[TBL] [Abstract][Full Text] [Related]
4. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
5. Severe myalgia associated with adalimumab treatment in a patient with Crohn's disease.
Hinojosa J; Borrás-Blasco J; Maroto N; Rosique-Robles JD; Alos R; Casterá ME
Ann Pharmacother; 2008 Jul; 42(7):1130-3. PubMed ID: 18492783
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
Casanova MJ; Chaparro M; Valenzuela C; Cisneros C; Gisbert JP
World J Gastroenterol; 2015 Feb; 21(7):2260-2. PubMed ID: 25717268
[TBL] [Abstract][Full Text] [Related]
7. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
8. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
Lim LL; Fraunfelder FW; Rosenbaum JT
Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity.
Patwala K; Crump N; De Cruz P
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28679512
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
12. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
[TBL] [Abstract][Full Text] [Related]
13. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
15. Henoch-Schönlein purpura during anti-TNFα therapy: a fortuitous event or an indication to stop therapy?
Pinheiro RR; Lencastre A
Eur J Dermatol; 2017 Jun; 27(3):304-305. PubMed ID: 28468732
[No Abstract] [Full Text] [Related]
16. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease.
Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Muriel-Herrero A; Gisbert JP
J Crohns Colitis; 2012 Oct; 6(9):950-3. PubMed ID: 22537636
[TBL] [Abstract][Full Text] [Related]
17. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.
Galor A; Perez VL; Hammel JP; Lowder CY
Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
19. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
Lazebnik LB; Sagynbaeva VÉ
Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
[TBL] [Abstract][Full Text] [Related]
20. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review.
Alzaga Fernandez AG; Demirci H; Darnley-Fisch DA; Steen DW
Cornea; 2010 Oct; 29(10):1189-91. PubMed ID: 20628295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
